NO20081307L - RNA antagonist sammensetninger for hemming av APO-B100 ekspresjon - Google Patents

RNA antagonist sammensetninger for hemming av APO-B100 ekspresjon

Info

Publication number: NO20081307L
Authority: NO; Norway
Prior art keywords: apo; expression; oligonucleotides; inhibition; lung
Prior art date: 2005-09-15

Application number

NO20081307A

Other languages

English (en)

Norwegian (no)

Inventor

Henrik Frydenlund Hansen

Majken Westergaard

Bo Hansen

Christoph Rosenbohm

Ellen Marie Straarup

Original Assignee

Santaris Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-15

Filing date

2008-03-12

Publication date

2008-03-12

2008-03-12 Application filed by Santaris Pharma As filed Critical Santaris Pharma As

2008-03-12 Publication of NO20081307L publication Critical patent/NO20081307L/no

Links

230000014509 gene expression Effects 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 2
239000005557 antagonist Substances 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
108020004707 nucleic acids Proteins 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000039446 nucleic acids Human genes 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
210000004072 lung Anatomy 0.000 abstract 2
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
206010033128 Ovarian cancer Diseases 0.000 abstract 1
206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
239000000074 antisense oligonucleotide Substances 0.000 abstract 1
238000012230 antisense oligonucleotides Methods 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
210000000481 breast Anatomy 0.000 abstract 1
210000001072 colon Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000005549 deoxyribonucleoside Substances 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
210000003734 kidney Anatomy 0.000 abstract 1
210000004185 liver Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000002018 overexpression Effects 0.000 abstract 1
210000002307 prostate Anatomy 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
210000000278 spinal cord Anatomy 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1
230000002381 testicular Effects 0.000 abstract 1
210000001685 thyroid gland Anatomy 0.000 abstract 1
210000003932 urinary bladder Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20081307A 2005-09-15 2008-03-12 RNA antagonist sammensetninger for hemming av APO-B100 ekspresjon NO20081307L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US71801805P	2005-09-15	2005-09-15
US79621106P	2006-04-27	2006-04-27
DKPA200600598		2006-04-27
PCT/DK2006/000481 WO2007031081A2 (fr)	2005-09-15	2006-09-01	Composes antagonistes d'arn permettant d'inhiber l'expression de apo-bl00

Publications (1)

Publication Number	Publication Date
NO20081307L true NO20081307L (no)	2008-03-12

Family

ID=37492457

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20081307A NO20081307L (no)	2005-09-15	2008-03-12	RNA antagonist sammensetninger for hemming av APO-B100 ekspresjon

Country Status (10)

Country	Link
US (1)	US20090118213A1 (fr)
EP (1)	EP1931778A2 (fr)
JP (1)	JP2009507499A (fr)
KR (1)	KR20080068019A (fr)
AU (1)	AU2006291836B2 (fr)
CA (1)	CA2622583A1 (fr)
EA (1)	EA200800823A1 (fr)
IL (1)	IL189933A0 (fr)
NO (1)	NO20081307L (fr)
WO (1)	WO2007031081A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
US20050287558A1 (en)	2004-05-05	2005-12-29	Crooke Rosanne M	SNPs of apolipoprotein B and modulation of their expression
EA201100812A1 (ru)	2006-04-03	2012-06-29	Сантарис Фарма А/С	Фармацевтическая композиция
JP5198430B2 (ja)	2006-04-03	2013-05-15	サンタリスファーマアー／エス	ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
EP2458006B1 (fr)	2006-05-05	2018-06-20	Ionis Pharmaceuticals, Inc.	Composés et procédés pour moduler l'expression d'APOB
WO2008113830A1 (fr) *	2007-03-22	2008-09-25	Santaris Pharma A/S	Composés arn antagonistes pour l'inhibition de l'expression de l'apo-b100
DK2149605T3 (da)	2007-03-22	2013-09-30	Santaris Pharma As	Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
RU2015127794A (ru)	2007-03-24	2018-12-21	Касл Терапьютикс, ЭлЭлСи	Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
TW200848077A (en)	2007-05-01	2008-12-16	Santaris Pharma As	Compounds for the modulation of beta-cantenin expression
DK2623599T3 (en)	2007-10-04	2019-04-08	Roche Innovation Ct Copenhagen As	Micromirers
US8450290B2 (en)	2007-11-26	2013-05-28	Enzon Pharmaceuticals, Inc.	Methods for treating androgen receptor dependent disorders including cancers
WO2009068033A2 (fr)	2007-11-26	2009-06-04	Santaris Pharma A/S	Antagonistes basés sur les lna ciblant le récepteur de l'androgène
TW200927176A (en)	2007-12-03	2009-07-01	Santaris Pharma As	RNA antagonist compounds for the modulation of PIK3CA expression
WO2009109665A1 (fr)	2008-03-07	2009-09-11	Santaris Pharma A/S	Compositions pharmaceutiques pour le traitement de maladies associées aux microarn
WO2010012667A1 (fr)	2008-08-01	2010-02-04	Santaris Pharma A/S	Modulation à médiation par micro-arn de facteurs stimulateurs de colonies
WO2010076248A1 (fr)	2008-12-31	2010-07-08	Santaris Pharma A/S	Utilisation d'oligomères antisens apob lna pour le traitement des syndromes coronaires aigus
WO2010107838A1 (fr)	2009-03-16	2010-09-23	Isis Pharmaceuticals, Inc.	Ciblage de l'apolipoprotéine b pour la réduction de l'apolipoprotéine c-iii
EP2421970B1 (fr)	2009-04-24	2016-09-07	Roche Innovation Center Copenhagen A/S	Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons
JP2012529279A (ja) *	2009-06-12	2012-11-22	サンタリスファーマアー／エス	新規の強力な抗ａｐｏｂアンチセンス化合物
EP2456870A1 (fr)	2009-07-21	2012-05-30	Santaris Pharma A/S	Oligomères anti-sens ciblant pcsk9
WO2011048125A1 (fr)	2009-10-20	2011-04-28	Santaris Pharma A/S	Administration orale d'oligonucléotides de lna thérapeutiquement efficaces
WO2011054811A1 (fr)	2009-11-03	2011-05-12	Santaris Pharma A/S	Traitement combiné par des antagonistes d'arn ciblant hsp-27
JP2011155914A (ja) *	2010-02-01	2011-08-18	Osaka Univ	脂質異常症治療薬剤としての化学修飾ｓｉＲＮＡ
US10017764B2 (en)	2011-02-08	2018-07-10	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
CN103946952A (zh)	2011-09-16	2014-07-23	宾夕法尼亚大学董事会	用于治疗癌症的rna改造的t细胞
AU2013324716B2 (en)	2012-09-26	2019-06-13	Guandong Mijinjia Biotechnology Co., Ltd	Oligomers with improved off-target profile
HK1214297A1 (zh)	2012-11-15	2016-07-22	Roche Innovation Center Copenhagen A/S	寡核苷酸缀合物
AU2014211406B2 (en)	2013-01-30	2019-07-18	Roche Innovation Center Copenhagen A/S	LNA oligonucleotide carbohydrate conjugates
EA031393B1 (ru) *	2013-05-01	2018-12-28	Глэксо Груп Лимитед	Композиции и способы модулирования экспрессии hbv и ttr
WO2014207232A1 (fr)	2013-06-27	2014-12-31	Santaris Pharma A/S	Oligomères antisens et conjugués ciblant pcsk9
CN105722980A (zh) *	2013-11-14	2016-06-29	罗氏创新中心哥本哈根有限公司	Apob反义缀合物化合物
EP4303229A3 (fr)	2014-01-21	2024-04-17	Novartis AG	Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe
EP3476939A4 (fr) *	2016-07-08	2019-06-05	Tak-Circulator Co., Ltd.	Acide nucléique inhibant l'expression du gène mex3b, inhibiteur d'expression du gène mex3b, procédé inhibant l'expression du gène mex3b, agent de prévention ou de traitement des maladies provoquées par l'expression du gène mex3b
EP3483283B1 (fr)	2016-07-08	2025-08-27	Tak-Circulator Corporation	Procédé de criblage d'agents pour la prévention ou le traitement de maladies provoquées par l'interleukine 6, l'interleukine 13, le tnf, le g-csf, la cxcl1, la cxcl2 ou la cxcl5 et agent pour la prévention ou le traitement de maladies provoquées par l'interleukine 6, l'interleukine 13, le tnf, le g-csf, la cxcl1, la cxcl2 ou la cxcl5
JP7372920B2 (ja)	2017-12-29	2023-11-01	セレクティス	Ｃａｒｔ細胞の作製を改良するための方法
SG11202006526YA (en)	2018-01-12	2020-08-28	Bristol Myers Squibb Co	Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2019140236A1 (fr)	2018-01-12	2019-07-18	Bristol-Myers Squibb Company	Oligonucléotides antisens ciblant l'alpha-synucléine et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5108921A (en) *	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US20020068709A1 (en) *	1999-12-23	2002-06-06	Henrik Orum	Therapeutic uses of LNA-modified oligonucleotides
US7407943B2 (en) *	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
DK2264172T3 (da) *	2002-04-05	2017-11-27	Roche Innovation Ct Copenhagen As	Oligomerforbindelser til modulering af HIF-1á-ekspression
WO2004091515A2 (fr) *	2003-04-09	2004-10-28	Alnylam Pharmaceuticals, Inc.	Conjugues arni
WO2006036916A2 (fr) *	2004-09-24	2006-04-06	Alnylam Pharmaceuticals, Inc.	Modulation d'arni d'apob et utilisations correspondantes

2006
- 2006-09-01 AU AU2006291836A patent/AU2006291836B2/en not_active Ceased
- 2006-09-01 WO PCT/DK2006/000481 patent/WO2007031081A2/fr not_active Ceased
- 2006-09-01 US US12/066,852 patent/US20090118213A1/en not_active Abandoned
- 2006-09-01 JP JP2008530329A patent/JP2009507499A/ja not_active Withdrawn
- 2006-09-01 EA EA200800823A patent/EA200800823A1/ru unknown
- 2006-09-01 EP EP06775966A patent/EP1931778A2/fr not_active Withdrawn
- 2006-09-01 CA CA002622583A patent/CA2622583A1/fr not_active Abandoned
- 2006-09-01 KR KR1020087009039A patent/KR20080068019A/ko not_active Withdrawn
2008
- 2008-03-04 IL IL189933A patent/IL189933A0/en unknown
- 2008-03-12 NO NO20081307A patent/NO20081307L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2006291836A1 (en)	2007-03-22
WO2007031081A3 (fr)	2007-05-18
AU2006291836B2 (en)	2012-02-23
EP1931778A2 (fr)	2008-06-18
KR20080068019A (ko)	2008-07-22
JP2009507499A (ja)	2009-02-26
CA2622583A1 (fr)	2007-03-22
WO2007031081A2 (fr)	2007-03-22
US20090118213A1 (en)	2009-05-07
IL189933A0 (en)	2008-08-07
EA200800823A1 (ru)	2008-10-30

Publication	Publication Date	Title
NO20081307L (no)	2008-03-12	RNA antagonist sammensetninger for hemming av APO-B100 ekspresjon
MXPA05008319A (es)	2006-02-28	Compuestos oligomericos para la modulacion de la expresion de survivina.
WO2004069992A3 (fr)	2005-04-21	Composes oligomeriques destines a la modulation de l'expression de ras
WO2008144507A3 (fr)	2009-05-14	Inhibiteurs de spirooxindole de kinase de l'aurore
WO2012174256A3 (fr)	2013-02-21	Profils de méthylation de l'adn dans le cancer
WO2009151598A8 (fr)	2010-05-06	Diazacarbazoles et procédés d’utilisation
WO2012016133A3 (fr)	2012-04-26	Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
WO2007134210A3 (fr)	2008-03-20	Méthodes et compositions destinées au diagnostic et au traitement du cancer
MX349550B (es)	2017-08-02	1,7-diazacarbazoles y metodos de uso.
WO2012061557A3 (fr)	2013-11-14	Composés chimiques
WO2007127010A3 (fr)	2008-07-31	Composés de diarylthiohydantoïne
WO2008008430A3 (fr)	2008-12-11	Procédés et compositions à base de micro-arn pour le diagnostic et le traitement de maladies apparentées au cancer du côlon
WO2009011850A3 (fr)	2009-03-05	Nouveaux composés thérapeutiques
WO2009154835A3 (fr)	2010-04-29	Compositions et procédés liés à mir-16 et à la thérapie contre le cancer de la prostate
WO2005113816A3 (fr)	2007-08-09	Methodes de diagnostic ou de traitement du cancer de la prostate au moyen du gene erg, seul ou combine a d'autres genes surexprimes ou sous-exprimes dans le cancer de la prostate
WO2013093508A3 (fr)	2013-10-24	Inhibiteurs de la voie wnt
WO2005000088A3 (fr)	2005-03-03	Profil d'expression du cancer du pancreas
WO2006028655A3 (fr)	2006-08-31	Genes, compositions, kits, et methodes pour identification, evaluation, prevention et therapie du cancer de la prostate
WO2005116259A3 (fr)	2009-04-02	Utilisation du profilage de l'expression genetique pour prevoir les chances de survie d'un patient atteint d'un cancer
NZ592825A (en)	2013-01-25	A triazolothiadiazole inhibitor of c-met protein kinase
WO2011021177A3 (fr)	2011-05-19	Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2006133361A3 (fr)	2009-06-11	Utilisation du profilage de l'expression genique pour predire la survie d'un patient atteint de cancer
WO2009124281A3 (fr)	2009-12-30	Nouveaux anticorps contre la croissance tumorale dans un bloc cible, l’angiogenèse et la métastase du cancer
WO2012009663A3 (fr)	2013-08-08	Nouveaux composés pour traiter le cancer et d'autres maladies
WO2006039582A3 (fr)	2007-05-24	Compositions et methodes de diagnostic et de traitement du cancer du cerveau et d'identification de cellules souches neuronales

Legal Events

Date	Code	Title	Description
2011-05-09	FC2A	Withdrawal, rejection or dismissal of laid open patent application